Literature DB >> 19795099

[Heparin-induced thrombocytopenia type II with thrombosis in an intensive care patient: therapy management using the direct thrombin inhibitor argatroban].

S Heil1.   

Abstract

Heparin-induced thrombocytopenia (HIT) type II is a life-threatening complication of heparin therapy. The present case report describes the therapeutic management of HIT type II with thrombosis using the direct thrombin inhibitor argatroban in an intensive care patient after successful surgery of a ruptured infrarenal abdominal aortic aneurysm. Despite high dosing and long-term application of argatroban, anticoagulation remained uncritical and was well controllable by monitoring the activated partial thromboplastin time. In consideration of the pharmacological characteristics, therapy suspension due to invasive interventions and switching to an oral vitamin K antagonist by defined algorithm resulted in an effective management.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19795099     DOI: 10.1007/s00101-009-1624-y

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  10 in total

1.  Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings.

Authors:  G K Lo; D Juhl; T E Warkentin; C S Sigouin; P Eichler; A Greinacher
Journal:  J Thromb Haemost       Date:  2006-04       Impact factor: 5.824

Review 2.  [Argatroban: pharmacological properties and anaesthesiological aspects].

Authors:  S Kleinschmidt; B Stephan; G Pindur; C Bauer
Journal:  Anaesthesist       Date:  2006-04       Impact factor: 1.041

Review 3.  Think of HIT.

Authors:  Theodore E Warkentin
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2006

4.  Argatroban for anticoagulation in continuous renal replacement therapy.

Authors:  Andreas Link; Matthias Girndt; Simina Selejan; Alexander Mathes; Michael Böhm; Hauke Rensing
Journal:  Crit Care Med       Date:  2009-01       Impact factor: 7.598

5.  Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time.

Authors:  Sebastian Harder; Jochen Graff; Ute Klinkhardt; Nils von Hentig; Jeanine M Walenga; Hikari Watanabe; Masanori Osakabe; Hans-Klaus Breddin
Journal:  Thromb Haemost       Date:  2004-06       Impact factor: 5.249

Review 6.  A critical evaluation of assays for detecting antibodies to the heparin-PF4 complex.

Authors:  John L Francis
Journal:  Semin Thromb Hemost       Date:  2004-06       Impact factor: 4.180

7.  Influence of direct thrombin inhibitor argatroban on coagulation assays in healthy individuals, patients under oral anticoagulation therapy and patients with liver dysfunction.

Authors:  Robert Siegmund; Klas Boer; Katrin Poeschel; Gunter Wolf; Thomas Deufel; Michael Kiehntopf
Journal:  Blood Coagul Fibrinolysis       Date:  2008-06       Impact factor: 1.276

8.  Argatroban anticoagulation in critically ill patients.

Authors:  Martin Beiderlinden; Tanja A Treschan; Klaus Görlinger; Jürgen Peters
Journal:  Ann Pharmacother       Date:  2007-04-17       Impact factor: 3.154

Review 9.  [Direct thrombin inhibitors: pharmacology and application in cardiovascular anesthesia].

Authors:  S A Kozek-Langenecker
Journal:  Anaesthesist       Date:  2008-06       Impact factor: 1.041

10.  Treatment of heparin-induced thrombocytopenia: a critical review.

Authors:  Jack Hirsh; Nancy Heddle; John G Kelton
Journal:  Arch Intern Med       Date:  2004-02-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.